Immunotherapy Toxicities and CRS ICANS Case Lab
Key Takeaways
- Immune checkpoint inhibitors can cause inflammatory toxicities in any organ system and may appear during or after treatment.
- CAR T-cell and bispecific antibody therapies require rapid recognition of cytokine release syndrome and neurotoxicity.
- Fever, hypoxia, hypotension, confusion, seizure, and handwriting or orientation changes need prompt grading and escalation.
- Do not give corticosteroids, antipyretics, or immunosuppressive therapy outside protocol and provider direction.
- Patient education must include delayed toxicity reporting, wallet cards, emergency contact pathways, and medication reconciliation.
Case Lab: Immunotherapy Toxicities, CRS, And ICANS
Case Snapshot
A 67-year-old patient receiving pembrolizumab for metastatic lung cancer calls with six watery stools per day, cramping, and fatigue. In the infusion center, another patient is day 3 after CAR T-cell therapy and develops fever 39.2 C, new oxygen requirement, and mild confusion. Both situations involve immune-based therapy, but the nursing priorities differ by syndrome and severity.
Immune Checkpoint Inhibitor Toxicities
Checkpoint inhibitors activate immune response against cancer but can also inflame normal tissue. Toxicities may involve skin, colon, liver, lungs, endocrine organs, kidneys, heart, neurologic system, eyes, or joints. Timing is variable. Symptoms can occur early, late, after therapy ends, or after a patient presents to an emergency department where the treatment history is unknown.
| Symptom Pattern | Possible Toxicity | Nursing Priority |
|---|---|---|
| Diarrhea, abdominal pain, blood, fever | Immune-mediated colitis | Hold routine assumptions, assess severity, notify provider |
| Cough, dyspnea, hypoxia | Pneumonitis | Urgent assessment and escalation |
| Headache, severe fatigue, dizziness, hypotension | Endocrinopathy or adrenal crisis | Evaluate severity, labs per order, urgent provider contact |
| Jaundice, dark urine, right upper quadrant pain | Hepatitis | Stop casual acetaminophen advice, notify provider |
| Chest pain, palpitations, syncope | Myocarditis or arrhythmia | Emergency evaluation |
The patient with six watery stools per day should not be told to simply take over-the-counter loperamide and continue therapy without evaluation. The nurse assesses stool count above baseline, hydration, fever, blood, abdominal pain, dizziness, medications, infection risk, and ability to maintain intake. The provider should be notified because immune-mediated colitis may require treatment hold, stool testing, corticosteroids, or higher level care. RN scope includes assessment, education, triage, and protocol-based instructions, not independently diagnosing colitis or prescribing steroids.
CRS Recognition
Cytokine release syndrome can occur after CAR T-cell therapy and some bispecific antibodies. Fever is often the first sign. Severity depends on hypotension, oxygen requirement, organ dysfunction, and response to interventions. The nurse should know the product-specific monitoring window, fever instructions, emergency contacts, and whether tocilizumab or corticosteroids are available per protocol.
For the day 3 CAR T-cell patient with fever and new oxygen need, the priority is immediate assessment and escalation. Obtain vital signs, oxygen saturation, hemodynamic status, mental status, infection workup orders, IV access, and provider notification. Sepsis and CRS can look similar, and both may require urgent action. The nurse should not dismiss fever as expected or give acetaminophen without considering masking, culture timing, and protocol.
ICANS Recognition
Immune effector cell-associated neurotoxicity syndrome can include confusion, word-finding difficulty, tremor, handwriting changes, decreased level of consciousness, seizure, cerebral edema, or motor weakness. Frequent neurologic checks and standardized tools are used per policy. A small change matters. A patient who cannot name the year, write a sentence as usual, or follow commands needs escalation.
Patient Education
Patients receiving checkpoint inhibitors need plain instructions to report diarrhea, cough, shortness of breath, rash, jaundice, severe fatigue, headache, vision changes, mood or cognition changes, chest pain, or decreased urine. They should carry immunotherapy information and tell all clinicians about treatment. They should avoid starting steroids, antidiarrheals, supplements, or antibiotics without oncology guidance unless instructed.
Patients after CAR T-cell therapy or bispecific antibodies need instructions about fever, neurologic changes, caregiver monitoring, driving restrictions, proximity to treatment center if required, infection precautions, and emergency presentation. Caregivers should know that confusion, tremor, seizure, severe sleepiness, hypotension symptoms, or breathing trouble requires urgent contact. Written instructions reduce missed details during stressful transitions.
Documentation And Reassessment
Document baseline and current symptoms, therapy type and date, severity grade elements, vital signs, neurologic findings, stool count, oxygen needs, provider notification, orders, patient response, and education. Reassessment is essential because CRS and ICANS can worsen quickly. The safest OCN response links recognition to action: assess severity, follow protocol, escalate early, avoid masking symptoms without direction, and continue reassessment.
A patient on pembrolizumab reports six watery stools per day with cramping. What is the best nursing action?
A day 3 CAR T-cell therapy patient develops fever, new oxygen requirement, and confusion. What syndrome must the nurse urgently consider?
Which teaching point is most important for a patient receiving immune checkpoint inhibitor therapy?